Confusion surrounds regulation of various types of drug makers

Stateline: Big Drug Companies Poorly Regulated
Far from triggering a quick fix, the deaths or illnesses of 620 people in 19 states that have been linked to a Massachusetts pharmacy have only underscored confusion over how to regulate the various types of drug-makers in the United States. All that's clear at the moment is that the present federal-state regulatory divide isn't working. "This is the time that we have to get this right," Cody C. Wiberg, executive director of the Minnesota Board of Pharmacy, said last month after attending a hearing convened by the U.S. Food and Drug Administration. One of the ideas the FDA floated at that hearing was a bigger role for states in the regulation of drug-making, a role for which some believe they are ill-equipped (Ollove, 1/3).

http://www.kaiserhealthnews.orgThis article was reprinted from with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.


Posted in: Healthcare News | Pharmaceutical News

Tags: , ,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
You might also like... ×
New research reveals impact of 3D printing technology in medical devices and pharmaceutical sector